An inhibitor of p110β, a catalytic subunit known to play a key role in driving the hyperactive signaling of the PI3K pathway in FXS, was able to ameliorate the protein synthesis defects in FXS NPCs [21]. The gene discussed is PIK3CB; the disease is fragile X syndrome.